Omniab, Inc. · NASDAQ:OABI
Omniab — Q3 2026 Earnings Presentation
27 slides from Omniab's earnings presentation, Oct 30, 2026
Slide 1: Q3 2026 Financial Results & Business Update
1 Q3 2026 Financial Results & Business Update Nasdaq: OABI October 30, 2026
Slide 2: Disclaimer
2 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, including our financial guidance fo
Slide 3: Introduction
3 Introduction Matt Foehr
Slide 4: Q3 Highlights
4 Q3 Highlights Differentiated technology platforms driving growth and progression of partnerships and programs xPloration®, now available to all customers, creating broader market and growth potential OmniTides platform launch extends to new high-value markets Continued business performance resulti
Slide 5: OmniAb Technologies
OmniAb Technologies 5 INNOVATION THAT ENABLES THE DISCOVERY OF NEXT GENERATION THERAPEUTICS BIOLOGICAL INTELLIGENCE Create Screen Deliver Custom In Vivo Libraries for High Throughput Prioritization of Candidates Antibody & Peptide Discovery Identification of Hits Custom Bioinformatics Conventional A
Slide 6: Active Partners
6 Active Partners Number of Active Partners(1)(2) 111 Partner Type Academic Commercial 4% 100 • 111 Active Partners as of 9/30/2026 21% Discovery • New licenses added in Q3 included Yemaya, Inc. n=111 75% and Monash University. New additions balanced by the business combination of two existing 50 Pa
Slide 7: Active Programs
7 Active Programs Number of YTD 2026 Change in Active Programs(1) Active Programs 433 38 433 • 433 Active Programs as of 9/30/2026 400 407 (12) • >98% of our Active Programs have contracted future economics to OmniAb 200 • Over $3 billion in total contracted potential milestones(2) • Average royalty
Slide 8: Active Clinical Programs and Approved Products
8 Active Clinical Programs and Approved Products Number of Active Clinical Programs and Approved Products(1)(2) 34 30 • 34 active clinical programs and approved products as of 9/30/2026 • Four new clinical additions so far in 2026, others expected in the near-term • Active clinical programs have ~$3
Slide 9: Clinical and Commercial-Stage Partner Pipeline
Clinical and Commercial-Stage Partner Pipeline 9 (1)(2) AS OF 9/30/2026 ONLY PROGRAMS WITH DOWNSTREAM ECONOMICS ARE SHOWN Phase Phase Phase11 1/1b Phase 1/2 1/2 Phase 2 Phase 3 Registration Approved 1/1b Hanall Biopharma CStone Pharmaceuticals, Zhikang Hongyi (Biocity) CessationTherapeutics Zhikang
Slide 10: Select Partner Updates
10 Select Partner Updates(1) IMVT-1402 TEV-’408 Precemtabart tocentecan Batoclimab FcRn IL-15 CEACAM5 ADC FcRn Immunovant expects to provide Teva Pharmaceuticals announced At the American Society of Clinical Harbour BioMed announced that the further updates on the potentially positive topline result
Slide 11: OmniAb's Pillars of Value
11 OmniAb’s Pillars of Value OmniAb is well-positioned to deliver for our stakeholders, with highly differentiated technologies and multiple ways to efficiently drive value Pipeline & Partnerships Discovery Technologies xPloration Platform Substantial contracted downstream Expanding suite of innovat
Slide 12: xPloration
12 xPloration Amechi Nwachuku
Slide 13: xPloration
13 xPloration • Consistently positive feedback Value Drivers Include: from users including Big Pharma, global CROs, and specialty biotech Higher Throughput(1) ‒ Live demos converting interest Easier to Use into placements More Robust • Unit placement and sale in Q3 to a Lower Cost top big pharma A g
Slide 14: xPloration Revenue Streams
14 xPloration Revenue Streams Instruments Consumables Software Service Capital sale of the Proprietary chips and Analysis and data Installation, training, and xPloration system materials used each run management subscriptions preventive maintenance Anchors the customer Recurring, usage-based Expands
Slide 15: xPloration: Positioned to Deliver Durable Revenue Streams
15 xPloration POSITIONED TO DELIVER DURABLE REVENUE STREAMS in millions Expected xPloration Revenue • xPloration revenue is expected to double in 2027 and to double again in 2028 • Recurring revenue is expected to become a long-term $2-$3 growth driver
Slide 16: Financial Updates
16 Financial Updates Kurt Gustafson
Slide 17: Q3 2026 Revenue
17 Q3 2026 Revenue $ in millions $4.0 $4 xPloration • License and Milestone revenue decreased due to a decrease in license fee revenue License & Milestone xPloration $2.2 • xPloration revenue increased on higher instrument sales and related consumables $2 License & Milestone Service • Service revenu
Slide 18: September 2026 YTD Revenue
18 September 2026 YTD Revenue $ in millions $31.8 xPloration $30 • License and Milestone revenue increased primarily due to an increase in milestone revenue $20 License & Milestone • xPloration revenue increased on higher instrument sales and related consumables xPloration $10.3 $10 License & • Serv
Slide 19: Q3 2026 Costs and Operating Expense (GAAP)
19 Q3 2026 Costs and Operating Expense (GAAP) $ in millions $20.4 $20.4 $20 • R&D expense decreased primarily due to lower personnel Other Other expense related to share-based compensation and salary expense and lower facility-related costs G&A • G&A expense increased primarily due to higher externa
Slide 20: September 2026 YTD Costs and Operating Expense (GAAP)
September 2026 YTD Costs and Operating Expense 20 (GAAP) $ in millions • R&D expense decreased primarily due to lower $63.5 $62.7 personnel expense related to share-based $60 Other Write-off (Q1) compensation and salary expense, lower external Other expenses primarily from certain antibody programs,
Slide 21: Q3 2026 and September 2026 YTD Financial Results
21 Q3 2026 and September 2026 YTD Financial Results 2025 2026 Q3 2025 Q3 2026 Variance Variance (in millions, except per share data) YTD YTD License and milestone revenue $ 0.6 $ 0.1 ($ 0.5) $ 3.9 $ 21.6 $ 17.7 Service revenue 1.2 2.8 1.6 5.0 7.4 2.4 xPloration revenue 0.1 0.7 0.6 0.7 1.9 1.2 Royalt
Slide 22: Q3 2026 Cash Costs and Operating Expense (Non-GAAP)
22 Q3 2026 Cash Costs and Operating Expense (Non-GAAP) GAAP TO NON-GAAP RECONCILIATION (in millions) Q3 2025 Q3 2026 2025 YTD 2026 YTD Costs and operating expenses (GAAP) $20.4 $20.4 $63.5 $62.7 Less: Depreciation of property and equipment 0.9 0.6 2.7 1.7 Less: Amortization of intangible assets 3.2
Slide 23: Balance Sheet
23 Balance Sheet (in millions) December 31, September 30, 2025 2026 ASSETS Current assets: Cash & investments $ 54.0 $ 64.2 Accounts receivable, net 7.4 2.6 Other current assets 3.9 4.2 Goodwill & intangible assets 209.1 197.0 PPE & leases 25.0 21.8 Other assets 1.5 1.1 Total assets $ 300.9 $ 290.9
Slide 24: Updated 2026 Guidance
24 Updated 2026 Guidance • We now expect Total Revenue to be in the range of $35 to $39 million • We now expect Costs and Operating Expense to be in the range of $83 to $87 million • We now expect Cash Costs and Operating Expense(1) to be in the range of $50 to $54 million • We now expect year-end c
Slide 25: Strong Financial Performance: Update to 2026 Guidance
Strong Financial Performance 25 UPDATE TO 2026 GUIDANCE in millions in millions in millions Costs & Cash Costs & Net Cash Flow Revenue Operating Expense Operating Expense(1) $35-$39 $100.9 $20 $40 $100 $100 $32-$36 $87.6 $83-$87 $84-$88 -$1 to +$3 $0 $26.4 $60.3 -$1 to -$5 $51-$55 $50-$54 $51.7 $20
Slide 26: Q&A
Omni Q&A
Slide 27: Omni >
Omni >